LeMaitre Vascular, Inc. LMAT

LeMaitre Vascular (LMAT) closed at $80.58 after a 14% 90-day pullback. One-year TSR is down 7.29%, while 3- and 5-year TSRs remain up 54.81% and 56.88%, indicating cooling gains after earlier strength. The stock trades below analyst targets, with a fair value around $110 implying roughly 27% upside. Bulls cite a strong biologics and next-gen product pipeline, ongoing regulatory wins, and potential pricing power that could lift margins and long-term earnings. Bears warn upside may fade if pricing momentum slows or regulatory and supply hurdles limit uptake of key grafts. The analysis invites stress-testing the thesis against peers and valuation benchmarks. Valuation gap and potential catalysts could moderately influence sentiment and future performance, with risk from pricing and regulatory hurdles.

LeMaitre Vascular addressed top five analyst questions from its Q2 earnings call. Q2 earnings call questions may shape investor views on operations and outlook.

LeMaitre Vascular, Inc. released its Q2 2026 earnings call transcript detailing quarterly financial results, operational updates, and management outlook. Quarterly earnings data and guidance can shift near-term stock sentiment without fundamentally changing long-term competitive position.

LeMaitre Vascular (LMAT) appears 31% undervalued after issuing updated earnings guidance and a dividend announcement. Earnings guidance and dividend updates can shift near-term investor sentiment and valuation perceptions for LMAT.

LeMaitre Vascular held its Q2 2026 earnings call covering quarterly financial results and operations. Quarterly earnings calls typically deliver moderate updates to financial outlook and investor views.

LeMaitre Vascular Inc (LMAT) posted strong EPS growth in its Q2 2026 earnings call, highlighting operational results and financial metrics. Strong EPS growth signals improved financial performance that can influence near-term market sentiment and valuation.

LeMaitre Vascular Q2 earnings call covered financial results, revenue trends, product pipeline updates, and strategic outlook for vascular devices business. Quarterly earnings updates deliver financial metrics that can shift near-term sentiment without fundamentally altering long-term company trajectory.

LeMaitre Vascular (LMAT) reported Q2 earnings and revenues below estimates. Q2 earnings and revenue miss creates moderate near-term pressure on LMAT stock and sentiment.

LeMaitre Vascular missed Q2 CY2026 revenue estimates and its stock fell 11.6%. Single-quarter revenue miss produces immediate stock reaction but leaves long-term operations and strategy unchanged.

LeMaitre Vascular reports Q2 2026 financial results. Quarterly financial results typically affect short-term stock sentiment and valuation metrics without altering long-term strategy.

Analysts have lifted fair value targets for LeMaitre Vascular (LMAT), shifting the company's story and indicating a more positive outlook. Raised analyst targets may moderately boost LMAT market sentiment without altering core operations.

LeMaitre Vascular (LMAT) shares plunged 17.2% over four weeks due to market pressures and operational hurdles, but undervaluation, robust fundamentals, and growth catalysts signal strong turnaround potential. 17.2% four-week stock decline affects sentiment and near-term performance but balanced by turnaround indicators limiting long-term impact.

Analysts value LeMaitre Vascular, Inc. (NASDAQ:LMAT) at US$118 following recent results. Analyst price target update to US$118 after results moderately influences investor sentiment and stock trajectory.

LeMaitre Vascular (LMAT) attracts growth investors with three compelling reasons highlighting strong growth potential. Three growth reasons signal moderately positive influence on investor sentiment and market performance.

LeMaitre Vascular, Inc. released its Q1 2026 earnings call summary, detailing financial performance, revenue growth, operational highlights, and future outlook. Q1 earnings call summaries disclose key financial metrics, guidance, and strategic updates that significantly influence stock price and investor sentiment.

LeMaitre Vascular released Q1 earnings call highlights covering financial results, operational updates, and forward guidance. Q1 earnings highlights disclose financial performance and guidance, significantly shaping investor sentiment and stock trajectory.

LeMaitre Vascular (LMAT) topped Q1 earnings estimates. Topping Q1 earnings estimates signals strong financial performance, likely boosting investor sentiment and stock trajectory.

LeMaitre Vascular, Inc. (LMAT) released Q1 2026 financial results. Q1 2026 earnings disclosure reveals key financial metrics impacting stock valuation and growth outlook.

LeMaitre Vascular (LMAT) Q1 earnings preview outlines key metrics, growth expectations, guidance, and potential catalysts for investors to monitor. Q1 earnings previews shape investor expectations and can moderately influence LMAT's near-term stock performance and sentiment.

LeMaitre Vascular (LMAT) reports profit boost from strong operating leverage, potentially driving positive investor reactions amid improved margins and efficiency. Profit surge via operating leverage improves financial efficiency and signals robust growth potential, significantly lifting investor sentiment and stock trajectory.

LeMaitre Vascular (LMAT) is strengthening profitability in vascular disease treatment. Strengthening profitability in core vascular disease operations moderately boosts LMAT's financial performance and market sentiment.

LeMaitre Vascular (LMAT) delivered exceptional Q4 earnings in the surgical equipment and consumables specialty stocks sector, firing on all cylinders with strong performance across operations. LMAT's outstanding Q4 earnings highlight robust operational strength, poised to significantly enhance future financial performance and investor sentiment.

LeMaitre Vascular (LMAT) exhibits robust revenue growth of 23% year-over-year, expanding gross margins to 68%, and increasing net income, positioning it as a compelling buy with 12 hedge funds holding stakes and a low forward P/E ratio. Strong financial metrics and hedge fund interest signal moderate positive influence on market sentiment and performance without transformative changes.

LeMaitre Vascular (LMAT) stock jumped 16.4% after announcing a dividend hike and new share buyback plan, raising questions about whether this strengthens the bull case for the company. Dividend hike and buyback plan triggered 16.4% stock surge, signaling financial confidence and positively impacting investor sentiment and market performance.

LeMaitre Vascular (LMAT) investment story evolves with new analyst price targets and updated company guidance, signaling positive shifts in outlook and performance expectations. New analyst targets and guidance represent major strategic updates likely to significantly enhance LMAT's market performance and investor sentiment.

LeMaitre Vascular, Inc. (LMAT) Q4 2025 earnings call summary details quarterly financial results, revenue growth, profitability metrics, and forward-looking guidance. Q4 earnings call summary discloses critical financial outcomes and strategic outlook directly shaping LMAT's market performance and investor confidence.

LeMaitre Vascular reported Q4 earnings call highlights, detailing financial results, revenue growth, product performance, strategic initiatives, and outlook for 2024. Q4 earnings highlights disclose financial metrics, guidance, and strategic updates that significantly shape investor expectations and company trajectory.

LeMaitre Vascular (LMAT) reported robust growth and strategic initiatives in Q4 2025 earnings call highlights. Robust Q4 2025 growth and strategic moves signal major positive shifts in LMAT's financial trajectory and investor sentiment.

LeMaitre Vascular reported Q4 earnings results. Q4 earnings snapshots reveal key financial metrics that significantly affect stock performance and future outlook.

LeMaitre Vascular (NASDAQ:LMAT) delivered surprise Q4 CY2025 sales results, driving its stock price sharply higher. Q4 sales exceeded expectations and propelled stock surge, signaling strong financial momentum with significant influence on future performance.